The study indicated a potential therapeutic synergy between iron supplementation and SGLT2 inhibition, which could be beneficial for some patients with HFrEF to prevent iron deficiency and to treat anemia [89]. This evidence concerns the gene SLC5A2 and Iron deficiency anemia.